Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, 8200 Aarhus N, Denmark.
Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, 8200 Aarhus N, Denmark.
Int J Mol Sci. 2023 Sep 16;24(18):14179. doi: 10.3390/ijms241814179.
The fibrinolytic system is a key player in keeping the haemostatic balance, and changes in fibrinolytic capacity can lead to both bleeding-related and thrombosis-related disorders. Our knowledge of the fibrinolytic system has expanded immensely during the last 75 years. From the first successful use of thrombolysis in myocardial infarction in the 1960s, thrombolytic therapy is now widely implemented and has reformed treatment in vascular medicine, especially ischemic stroke, while antifibrinolytic agents are used routinely in the prevention and treatment of major bleeding worldwide. Despite this, this research field still holds unanswered questions. Accurate and timely laboratory diagnosis of disturbed fibrinolysis in the clinical setting remains a challenge. Furthermore, despite growing evidence that hypofibrinolysis plays a central role in, e.g., sepsis-related coagulopathy, coronary artery disease, and venous thromboembolism, there is currently no approved treatment of hypofibrinolysis in these settings. The present review provides an overview of the fibrinolytic system and history of its discovery; measurement methods; clinical relevance of the fibrinolytic system in diagnosis and treatment; and points to future directions for research.
纤溶系统是维持止血平衡的关键因素,纤溶能力的变化可导致出血相关和血栓形成相关疾病。在过去的 75 年中,我们对纤溶系统的认识有了极大的扩展。自 20 世纪 60 年代首次成功应用溶栓治疗心肌梗死以来,溶栓疗法现已广泛应用,并改革了血管医学的治疗方法,尤其是缺血性脑卒中,而抗纤维蛋白溶解剂在全球范围内常规用于预防和治疗大出血。尽管如此,该研究领域仍存在悬而未决的问题。在临床环境中准确和及时地对纤溶紊乱进行实验室诊断仍然是一个挑战。此外,尽管越来越多的证据表明低纤溶在例如脓毒症相关凝血障碍、冠状动脉疾病和静脉血栓栓塞症中起核心作用,但目前在这些情况下尚无批准用于低纤溶的治疗方法。本综述概述了纤溶系统及其发现史;测量方法;纤溶系统在诊断和治疗中的临床相关性;并指出了未来的研究方向。